Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells

Author(s):
Spender, L.C.; Ferguson, G.J.; Liu, S.J.; Cui, C.; Girotti, M.R.; Sibbet, G.; Higgs, E.B.; Shuttleworth, M.K.; Hamilton, T.; Lorigan, P.; Weller, M.; Vincent, D.F.; Sansom, O.J.; Frame, M.; Dijke, P. ten (0000-0002-2875-4723); Marais, R.; Inman, G.J.
Published
2016
Publication type
Article / Letter to editor
melanomaBRAFvemurafenibPLX-4720TGF-beta
Date issued
2016-12-13
Language
English
Is part of
Oncotarget (2016), Vol. 7, no. 50, p. 81995-82012
hdl
1887/113832
doi
10.18632/oncotarget.13226